IgG Fc (AA 99-330) (Active) protein (AVI tag,Biotin)

Catalog No. ABIN5674596

Product Details

Target: IgG Fc

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 99-330

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: AVI tag,Biotin

Brand: PrecisionAvi

Sequence: AA 99-330

Specificity: Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Characteristics: This protein carries an Avi tag at the C-terminus. The protein has a calculated MW of 28.4 kDa. The protein migrates as 36-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Purity: >95 % as determined by SDS-PAGE.

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Comment:

Ready-to-use AvitagTM biotinylated protein:
The product is exclusively produced using the AvitagTM technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.

This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Tris with Glycine, Arginine and NaCl,  pH 7.5

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

References

Mukundan, Guan, Singleton, Yang, Li, Parekkadan: "Artificial T Cell Mimetics to Combat Melanoma Tumor Growth." in: American journal of advanced drug delivery, Vol. 6, Issue 1, pp. 21-32, (2018) (PubMed).

Target Details

Target: IgG Fc

Target Type: Antibody

Background: Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.

Molecular Weight: 28.4 kDa